

Name: Prof. Meir Perez Pugatch

Date: Nov 2020

Curriculum Vitae and List of Publications**I. CURRICULUM VITAE****1. PERSONAL DETAILS**

Name: Meir Pugatch

Nationality: Israeli/German

Date of Birth: September, 1972

Marital Status: Married + 3 children

Permanent Home Address: 34 Levi Eshkol st, Tel-Aviv

Home Telephone Number: 03-7414525

Office Telephone Number: 03-6299294

Electronic Address: Fax Number: 03-6204395

2. HIGHER EDUCATION**A. Undergraduate and Graduate Studies**

Year of Approval of Degree	Degree	Name of Institution and Department	Period of Study
1994-1997	Tel-Aviv University, Department of Political Science	B.A., Political Science	June 1997
1997-1998	London School of Economics, Department of International Relations	MS.c., Politics of the World Economy- (Research Track)	November 1998
1998-2002	London School of Economics, Department of International Relations	Ph.D. International Political Economy	July 2002

B. Post-Doctoral Studies

None

3. ACADEMIC RANKS AND TENURE IN INSTITUTES OF HIGHER EDUCATION

Dates	Name of institution and department	Rank
2003 - 2004	Ben-Gurion University, Faculty of Health Sciences	Teaching Fellow
2004 - 2006	Hebrew University, Department of International Relations	Teaching Fellow
2004 – September 2006	University of Haifa, Faculty of Social Welfare and Health Sciences, School of Public Health	Lecturer (specialist track)
September 2006 to date	University of Haifa, Faculty of Social Welfare and Health Sciences, School of Public Health	Senior Lecturer (specialist track, 1/4 position)
July 2012	University of Haifa, Faculty of Social Welfare and Health Sciences, School of Public Health	Professor) (specialist track, 1/4 position)
October 2013	Department of International and European Law, Faculty of Law , Maastricht University	Professor (0.2 position)

4. SCHOLARLY POSITIONS AND ACTIVITIES IN UNIVERSITY

Dates	Institution	Role
2003 to date	University of Haifa, School of Public Health	Chair, Pfizer Forum For Public Health Policy
2007	Faculty of Social Welfare and Health Sciences	Chairman of an ad hoc committee appointed by the Dean of the Faculty of Social Welfare and Health Sciences to review different intellectual property aspects in the Faculty (Report was submitted to the Dean on September 2 nd 2007)
2009 to 2011	University of Haifa, School of Public Health	Co-Chair, Division of Management and Health Administration, School of Public Health
2011 to 2016	University of Haifa, School of Public Health	Head, Division of Health Systems Administration, School of Public Health
2013 to date	Department of International and European Law, Faculty of Law , Maastricht University	IPKM Professor of Valorization, Entrepreneurship and Management

*2019 to date	University of Haifa, School of Public Health	Head, Division of Health Management
---------------	--	-------------------------------------

5. SCHOLARLY POSITIONS AND ACTIVITIES OUTSIDE THE UNIVERSITY

Year	Position	Institution
Consultancy and advisory roles		
1998-2002	Intellectual property consultant – World Trade Organization Intellectual Property Negotiating Issues and Positions	Maxwell Stamp, London
2003 -2008	Intellectual property consultant	Chief Scientist Office, Ministry of Health, Medical Research Council
2003-2004	Intellectual property consultant – intellectual property policy-making	Enterprise LSE, London
2003 -2005	Intellectual property consultant	Ministry of Finance
2003-2005	Intellectual property advisor – trade policy of intellectual property rights	International Trade Policy Unit, London School of Economics
2003-2005	Intellectual property expert - intellectual property and pharmaceutical data exclusivity in the context of innovation and market access	International Centre for Trade and Sustainable Development (ICTSD), Switzerland
2004-2005	Drafting a Model Bill for the Israeli Parliament: Utilization and Transfer of Knowledge and Technologies Owned by Government and Public Bodies in Israel, (July2004)	Knesset Member, Meli Polishook Bloch, Chairman of the Science and Technology Committee
2004-2005	Intellectual property expert - International regulation of intellectual property rights	United Nations University – Comparative Regional Integration Studies (UNU-CRIS) Brussels

Year	Position	Institution
2006	Intellectual property consultant	The Israeli Patents, Designs and Trademark Authority
2006	Intellectual property consultant – EPO Scenarios Project	European Patent Office – EPO, Germany
2006	Intellectual property consultant – Assessment of Sweden's IP environment	Timbro, Sweden
2007	Intellectual property consultant - the US and EU's Approach to the International Regulation of Intellectual Property Trade-Related Agreements	The European Centre for International Political Economy (ECIPE)
2007	Intellectual property consultant	The IP Forum, The Federation of Israeli Chambers of Commerce
2090-2010	Project leader, global survey of licensing activities in selected fields of Environmentally Sound Technologies (ESTs)	Joint project by the United Nations Environment Programme (UNEP), the European Patent Office (EPO), and the International Centre for Trade and Sustainable Development (ICTSD)
2010	Intellectual property consultant to the World Intellectual Property Organization (WIPO), conducting a study on the Role of Intellectual Property Rights in the Transfer of Environmentally Sensitive Technologies (ESTs)	World Intellectual Property Organization
2011	Intellectual property consultant to the Institute for Globalization and International Regulation, Maastricht University. Conducting the economic chapter of the external study on the Anti-Counterfeiting Trade Agreement (ACTA), commissioned by the Directorate General for External Studies, Policy Department of the European Parliament	Institute for Globalization and International Regulation, Maastricht University

Year	Position	Institution
2012	Intellectual property consultant to Enterprise LSE (London School of Economics), preparing a report to the European Parliament, Directorate General for External Policies on The Anti-Counterfeiting Trade Agreement (ACTA) and its impact on access to generic medicines	Enterprise LSE
2013-2015	Intellectual property consultant to US Chamber of Commerce, Global Intellectual Property Center – creating the GIPC International IP Index	US Chamber of Commerce
2014-2015	Intellectual property consultant to the Biotechnology Industry Organization, BIO I	BIO, Washington DC
2016	Member of the IPKM Exam committee	University of Maastricht
2016 to date	Member of the European Intellectual Property Network (EIPN) Innovation Society - Principle Supervisor ESR 8; Second supervisor ESRs 6 and 3 http://www.eipin-innovationsociety.org/	European Intellectual Property Network (EIPN) Innovation Society
2016/7	Member of the advisory Committee to the OECD-OHIM project on counterfeiting	OECD-OHIM

Expert advisory roles: Professional committees, think-tanks, forums and taskforces		
2000-2003	Chair and coordinator of the ' <i>Israeli Pharmaceutical and Biotechnological Think-Tank</i> ', consisting of representatives of the Government (Ministries of Finance, Justice, Health and Trade and Industry), the pharmaceutical industry (Pharma Israel, Pfizer, Genzyme, MSD, Johnson and Johnson), voluntary organisations ('Patients' Rights'), Hospitals (Sheba Medical Centre, Rambam Medical Centre) and Healthcare Providers (Sick-Funds)	Chief Scientist Office, Ministry of Health
2002-2005	Member of the Steering Committee	Medical Research Council at Chief Scientist Office, Ministry of Health
2002 – 2005	Member of the Committee on Intellectual Property Rights in Hospitals	Ministry of Finance

2002-2005	Member of the Committee for Research in Hospitals	Chief Scientist Office, Ministry of Health, Medical Research Council
2004-2005	Member of the Ethics Committee	Rambam Medical Centre
2005-2011	Academic Advisor, the Merck-Stockholm Network Intellectual Property Programme	MSD Israel
2005 to date	Director of Research & Head of the Intellectual Property and Competition Programme	The Stockholm Network, United Kingdom www.stockholm-network.org
2008	Chairman of the Intellectual Property Grant Committee	Postgraduate Research Grants In the Field of Pharmaceutical Intellectual Property Rights - A Joint Collaboration between the Stockholm Network, Queen Mary Intellectual Property Research Institute and Maastricht University, Faculty of Law
2008	Member of the Committee for the Evaluation of the Need for Human Embryonic Stem Cells R&D Centres	Ministry of Health and the Forum of National Infrastructures (Telem)
2008-2009	A member of international research team	Catch Up and Intellectual Property Regimes, A Project Directed by Professor Richard Nelson of Columbia University and Professor Hiro Odagiri and collaborators from Hitotsubashi University (Tokyo, Japan)
2008-2009	Participant in an Ad Hoc Economic Advisory Group	European Patent Office
2008-2011	Member of the Patent Policy Forum of the Commissioner of Patents and Trademarks	Israeli Patent & Trademark Office

2012	Member of the Scientific Advisory Board	International Society For Pharmacoeconomics and Outcomes, Israel Chapter
2017	Member of the Mosaic committee for the creation publicly funded patient-centric databases	Ministry of Health, Israel
Editorial roles, review boards and refereeing		
2005 to date	Editor	Know-IP, the Stockholm-Network's monthly bulletin on intellectual property
2006 to date	Occasional referee	Review of International Political Economy
2006 to date	Occasional referee	Indian Journal of Intellectual Property Rights
2008 to date	Occasional referee	Edwar Elgar Publishers (series on Intellectual Property Rights) and Routledge (research level books)
2011 to date	Occasional referee	International Journal of Intellectual Property Management
2012 to date	Occasional referee	Oxford Economic Papers
2012 to date	Member of the Editorial Advisory Board	Journal of Commercial Biotechnology
*2020	Occasional referee	Routledge
*2020	Occasional referee	Maastricht Journal of European and Comparative Law
Activities in other academic institutions		

2009 -2013	Guest Lecturer	Masters Intellectual Property Law and Knowledge Management (LLM/MSc, Maastricht University Faculty of Law
2009 to date	Adjunct research fellow	Australian Global Studies Research Centre, University of Western Australia
2010 – 2011	Co-Moderator, Postgraduate Programme for Applied Biomedicine and Bioethics	Faculty of Medical Sciences, Ben Gurion University
*2014	Visiting Professor	Peking University School of Transitional Law (STL)
*2016	Visiting Professor	Beihang University School of Management
*2019-2021	Visiting Professor	China Intellectual Property Management Network, Nankai University (NKU), Tianjin, China

6. PARTICIPATION IN SCHOLARLY CONFERENCES

Clarifications – in this CV the term IP is the acronym of intellectual property and the term IPRs is the acronym of intellectual property rights

a. Active Participation

	Date	Name of Conference	Place of Conference	Subject of Lecture/Discussion/Comments
Local (Israel)				
1	14.10.2002	Pharmaline Conference on Direct to Consumer Advertising	Tel-Aviv	Speaker, Direct to Consumer Information or Direct to Consumer Advertising? The Benefits of Information; the Costs of Branding - Aspects of Intellectual Property Economics
2	14.05.2003	Symposium for Physicians, Conference on Biotechnology	Tel-Aviv	Speaker, Intellectual Property Rights as a Commercial Asset in Public Health Systems: Challenges and Opportunities in Public/Private Collaboration

	Date	Name of Conference	Place of Conference	Subject of Lecture/Discussion/Comments
3	6.01.2003	IsraPharm 2003 Conference on Life Sciences	Tel-Aviv	Speaker, Intellectual Property Rights and BioMedicine
4	4.03.2004	The Israeli Center of Management (HAMIL)	Tel-Aviv	Speaker, Intellectual Property and Biotechnology
5	13-14.06. 2004	The New IP Order - A Global Trade-Off, Haifa Center of Law & Technology	Herzeliya and Haifa	Speaker, The international Regulation of Intellectual Property Rights: Multilateral, Regional and Bilateral Preferences in Contemporary IP Trade-Related Negotiations
6	14.01.2005	Annual Conference of Heads of Professional Associations, Israel Medical Association	Tiberias	Chair , Panel on Intellectual Property in Hospitals
7	26.12.2006	New Technologies, Shaping the Medicines of the Future, Organised by Maccabi Healthcare Service	Ramat-Gan	Speaker, Challenges and Opportunities to Intellectual Property Pharmaceutical Policy-Making - Israel and the World
8	01.11.2007	Pharma Israel 2007 Annual Conference	Tel-Aviv	Chair , Panel on The Preferred Israeli Solution to Health Technology Assessment
9	11.11 2009	Pharma-Israel's Annual Conference – The Pharma Industry Looks to the Next Decade	Tel-Aviv	Chair , Industry Panel
10	10.03..2010	The 3rd Annual Conference of the Israeli Society for Pharmacoeconomics and Outcomes Research (ISPOR-Israel)	Herzliya	Moderator: What Is the Value of Preventive Medicine?
11	21.06.2010	Cost Benefit of Primary Intervention Programmes in the fields of Public Health and Health Promotion	University of Haifa Israel	Speaker, the Political Economy of Health Technology Assessment

	Date	Name of Conference	Place of Conference	Subject of Lecture/Discussion/Comments
12	21-22.02.2011	National Seminar the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS), co-organised by the World Trade Organization (WTO) and the Ministry of Trade and Labour	Jerusalem, Ministry of Trade and Labour	Chair and Moderator, Panel on Patents and Trade Secrets
13	3 March 2011	Patents and Inventions – "Inventing Money", In-Service Training Faculty for Lawyers, Ministry of Justice	Jerusalem	Speaker, What is the Value of Your Patent?
14	6 June 2011	The 27th Annual Meeting of the Israeli Economic society	Jerusalem	Speaker, The Political Economy of Health Technology Assessment – A Science or an Art?
*15	September 2012	WIPO-ILPTO Inter-Regional Seminar on Economic Issues of Intellectual Property Rights	Jerusalem	Economics of Patents in the 21st Century - Do We Need a Paradigm Shift?
*16	February 2103	Meeting of Israeli health journalists	Tel Aviv	Speaker and moderator: The pharmaceutical industry – challenges and opportunities
*17	April 2013	Risk-Sharing Agreements Workshop Program ISPOR Israel	Tel Aviv	What does it take to have real market entry agreements (so called "Risk Sharing") in Israel? Separating practice from rhetoric
*18	September 2015	Inter-Regional Seminar on Economic Issues of Intellectual Property Rights	Jerusalem	Economics of Patents in the 21st Century? Do We Need a Paradigm Shift?

	Date	Name of Conference	Place of Conference	Subject of Lecture/Discussion/Comments
International				
1	16-18.05. 2002	Second International Conference on Biotechnology and Investment	Moscow, Russia	Speaker, Global Developments in the Protection of Pharmaceutical and Biotechnological Intellectual Property Rights - the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)
2	7-8.07. 2003	The Commonwealth Trade Forum	London, UK	Speaker, Trade-Related Aspects of Intellectual Property Rights
3	31.07 – 1.08 2003	Institute of Southeast Asian Studies (ISEAS) Roundtable on the WTO's "Singapore" Issues and Trade Facilitation	The Institute of Southeast Asian Studies (ISEAS) Singapore	Speaker, Trade Agreements and Anti-competitive Practices
4	28.06.2004	London School of Economics Workshop on Intellectual Property Policy Fundamentals Supportive of the Pharmaceutical and Biomedical Industry in Advanced Developing Countries with Established R&D Capabilities	London, UK	Speaker, What Needs to be Researched in Relation to Intellectual Property Rights and Pharmaceuticals – "Defying" the Conventional Wisdom?
5	12-16.10 2004	The Third Bellagio Dialogue on Development and Intellectual Property	Rockefeller Foundation, Bellagio, Italy	Speaker, Intellectual Property and Pharmaceutical Data Exclusivity in the Context of Innovation and Market Access

	Date	Name of Conference	Place of Conference	Subject of Lecture/Discussion/Comments
6	17.12.2004	The United Nations University Conference on Comparative Research in Integration Studies and the London School of Economics	Brussels, Belgium	Speaker, the International Regulation of Intellectual Property Rights in a TRIPs and TRIPs <i>Plus</i> World
7	3.03.2005	Stockholm Network Round Table on Intellectual Property, Competition and Competitiveness	London, UK	Chair , Panel on Intellectual Property, Innovation, Monopoly and Competitiveness
8.	17.01.2006	The Progress and Freedom Foundation – Intellectual Property and Innovation in the Digital World	Prague, Czech Republic	Speaker, The Political Economy of Intellectual Property Policy Making
9	26.01.2006	Arts and Humanities Research Council (AHRC) - Copyright Research Network: Copyrights, Corporate Power and Human Rights	London, UK	Speaker, Political Economy of Intellectual Property Policy-Making – Theory and Practice
10	22-24.02 2006	CPTECH - The International Market Place and Conference for Technology Transfer Professionals	Cannes, France	Chair , Panel on US/EU approaches to University Licensing
11	23-25.08. 2006	International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Asian Regional Conference on Intellectual Property, Innovation and Health	Singapore	Speaker, Measuring the Strength of National Pharmaceutical Intellectual Property Regimes: Creating a new Pharmaceutical Intellectual Property Index

	Date	Name of Conference	Place of Conference	Subject of Lecture/Discussion/Comments
12	28.01.2007	The Gower's Review of Intellectual Property, a joint seminar by Managing Intellectual Property Magazine and the Stockholm Network	London, UK	Speaker, The Lisbon Agenda and the Gower's Review of Intellectual Property the Answer
13	20.02.2007	Debating Pharmaceutical Intellectual Property Rights , a joint workshop by the United Nations Conference on Trade and Development (UNCTAD) and the Stockholm Network	Geneva, Switzerland	Speaker & Organizer - the Economics of Pharmaceutical Intellectual Property Rights
14	19-20.04 2007	European Patent Office (EPO) - European Patent Forum (18/19 April 2007, Munich), Scenarios for the Future: The IP landscape in 2025	Munich, Germany	Speaker, Intellectual Property Policy and its Systems Worldwide
15	2.05.2007	Stockholm Network Amigo Society Meeting on the Lisbon Agenda	Brussels, Belgium	Chair , Panel on the Lisbon Agenda Strategies
16	22.10.2007	Defining the Public Interest in Intellectual Property - a joint event by the United Nations Conference on Trade and Development (UNCTAD), the Stockholm Network- and Public Interest Intellectual Property Advisors (PIIPA)	Geneva, Switzerland	Chair , Panel on Public Interest in Health- and Software-Related Intellectual Property Rights

	Date	Name of Conference	Place of Conference	Subject of Lecture/Discussion/Comments
17	3.10.2007	The Day After Tomorrow: The Legal, Economic and Technological Implications of the Ruling on Microsoft vs. the European Commission, a joint seminar by Managing Intellectual Property Magazine and the Stockholm Network	Brussels, Belgium	Chair , Panel on the Legal, Economic and Technological Implications of the Ruling on Microsoft vs. the European Commission
18	16.11.2007	Life Sciences Symposium – Intellectual Property and Life Science Regulation – a joint workshop by the World Intellectual Property Organization (WIPO) and the Stockholm Network	Geneva, Switzerland	Chair , Panel on Linkages between Product Regulation and the Patent System
19	12-13.11. 2008	“Catch Up and Intellectual Property Rights ” project, Second Tokyo Meeting. A Project Directed by Professor Richard Nelson of Columbia University and Professor Hiro Odagiri and collaborators from Hitotsubashi University (Tokyo, Japan) and the Hebrew University	Tokyo, Japan	Submission of paper by Pugatch, M.P., Teubal, M. <i>Israel's High Tech Catch Up Process – The Role of Intellectual Property Rights and Other Policies</i> , Draft paper (presented by Prof. Tobal)

	Date	Name of Conference	Place of Conference	Subject of Lecture/Discussion/Comments
20	17-18.03. 2008	The Conference Board of Canada, International Forum on the Creative Economy	Ottawa, Canada	Submission of paper by Pugatch, M.P. and Torstensson. D. The Good, the Bad, and the Ugly – How have policymakers dealt with the growing complexity of the Intellectual Property debate and the issue of online piracy?
21	18.11.2008	Meeting of the Economic Advisory Group, European Patent Office	Munich, Germany	Speaker, Patenting Strategies in the Pharmaceutical and Biotech Industries – Ever-greening or Incremental Innovation? And the Difference Between Them
22	8.05.2009	Study on Patents and environmentally sound technologies (EST) Consultation with industry and business associations – Joint project by the United Nations Environment Programme (UNEP), the European Patent Office (EPO), and the International Centre for Trade and Sustainable Development (ICTSD)	Geneva, Switzerland	Speaker, Creation of a Licensing Survey in the Field of environmentally Sound Technologies
23	8.06.2009	European Healthcare Reform Group Meeting, organised by the Stockholm Network	Brussels, Belgium	Speaker, Policy Implications of Healthcare Reform in Europe

	Date	Name of Conference	Place of Conference	Subject of Lecture/Discussion/Comments
24	19.10.2009	Study on Patents and environmentally sound technologies (EST) Consultation with industry and business associations – Joint project by the United Nations Environment Programme (UNEP), the European Patent Office (EPO), and the International Centre for Trade and Sustainable Development (ICTSD)	Geneva, Switzerland	Speaker, Interim Results of the Licensing Survey
25	23.02.2010	Are Your Medicines Safe, organised by the Stockholm Network	Brussels, Belgium	Speaker, Keeping Medicines Safe – A Study of the Regulations Guiding the Approval of Medicines in Emerging Markets
26	28.04.2010	Seminar on the Role of Patents in Investment and Transfer of Technologies, University of Rome Tre	Rome, Italy	Speaker, Intellectual Property Rights and Energy-Related Technologies - Implications for Policy
27	30.09.2010	Presentation of the study "Patents and Clean Energy: Bridging the Gap Between Evidence and Policy, A joint study by the United Nations Environment Programme (UNEP), the European Patent Office (EPO) and the International Centre for Trade and Sustainable Development (ICTSD)	Brussels, Belgium	Speaker, the Role of Patents in the Transfer of Clean Energy Technologies (CETs)

	Date	Name of Conference	Place of Conference	Subject of Lecture/Discussion/Comments
28	20.3.2011	Symposium on IP in the bioseed industry: Plant Varieties and Patents - Broccoli and Tomato, or who is privileged? Organised by the Institute for Globalization and International Regulation, Maastricht University	Maastricht University	Speaker
29	11-12.07.2011	World Intellectual Property Organization Conference on Innovation and Climate Change	Geneva, Switzerland	Speaker, IPRs and energy-related technologies - Implications for Policy
30	1.03.2011	The Anti Counterfeiting Trade Agreement (ACTA), Workshop by the European Parliament, Directorate General for External Relations, Policy Department and Committee on International Trade	European Parliament, Brussels, Belgium	The impact of the Anti-Counterfeiting Trade Agreement (ACTA) on access to medicines in developing countries
31	30 October 2012	Russian Academy of National Economic and Public Administration	Moscow	Leveraging and Enhancing Biopharmaceutical Innovation in Russia Challenges and Opportunities
32	22-23 rd April 2013	The 13th IEEM Intellectual Property Seminar Intellectual Property in an Open Society	Macau	Property vs. Equal Access – Pharmaceuticals and Climate Related Patents

	Date	Name of Conference	Place of Conference	Subject of Lecture/Discussion/Comments
33	21-23 May	Adam Smith Conferences' 19th annual international Russian Pharmaceutical Forum	St Petersburg, Russia	The Challenging Nature of the Pharmaceutical Business Implications for Emerging Markets
34	24 June 2013	2013 EFPIA Annual General Meeting	Brussels	Panel on health and growth
35	30 th September 2013	AACCLA's 46th Annual Meeting U.S. Chamber of Commerce	Washington DC	Developing a Global Business Rule of Law Dashboard
36	13-14 November 2013	The Essentials of IP, for EU Officials – co-organized by the EPO and the Office for Harmonization in the Internal Market	Brussels, Belgium	IP policies for a knowledge economy in and outside Europe
37	May 2014	<i>Trade Secrets, Restrictive Covenants and the Knowledge Economy</i>	Macau	Trade Secrets, Restrictive Covenants and the Knowledge Economy
38	June 2014	<i>Advancing Life Sciences Through Policy Development- Proceedings from an International Stakeholder Dialogue, June 23, 2014, La Jolla, California</i>	California	Building the Bioeconomy
39	February 2015	US Chambers of Commerce – Global IP Center	Delhi, India	Introducing the third edition of the GIPC International IP Index
40	October 2015	<i>Approaches to securing investment - Meir presentation, Interparliamentary Committee meeting, Oct 2015</i>	Moscow Russia	Strengthening investment conditions through effective policy-making

	Date	Name of Conference	Place of Conference	Subject of Lecture/Discussion/Comments
41	April 20015	<i>EIPIN Meeting, April 2015</i>	Munich, Germany	Pharmaceutical Innovation and Regulatory Data Protection – Friends or Foes?
42	November 2015	<i>The 15th IEEM Intellectual Property Seminar</i>	Macau	Extortion rackets in IP: Promoting the Wrong Kind of Creative Ideas
43	January 2016	US-India Business Council	Delhi	Building the Bio economy in India
44	February 2016	US Chamber of Conference	Washington, DC	Measuring IPRs on a global scale – Launch of the GIPC IP Index
45	March 2016	US Chamber of Conference- WTO TRIPS council	Geneva	Measuring IPRs on a global scale – Launch of the GIPC IP Index
46	April 2016	ISPOR 2016	Tel Aviv	Value Based Pricing in Israel
47	May 2016	Beihang University	Beijing	Curriculum talk - Policy, economics and knowledge creation in biomedical field - Considering China in a global context
48	September 2016	OPPI Roundtable on National IPR Policy	Delhi	Developing a national biopharmaceutical eco-system and the role of IPRs
49	6 June 2016	<i>BIO International Meeting- ICBA Ministerial Meeting</i>	San Francisco, US	Building the Bioeconomy – policies and best practices
50	September 2016	Inaugural speech Maastricht University	Maastricht	IP, Monopolies and the Knowledge Economy Sink or Swim
*51	February 2017	Industry-Government Meeting	Ankara	Leveraging the Bioeconomy in Turkey
*52	February 2017	US –Chambers of Commerce	Washington DC	Launch of the 5 th Edition of the GIPC Index
*53	April 2017	Join Meeting of the US Chambers and the US Government	Washington DC	Presenting the US Chambers Score for the US
*54	May 2017	EIPIN IS PhD Interviews and management meeting	Alicante, US	

	Date	Name of Conference	Place of Conference	Subject of Lecture/Discussion/Comments
*55	June 2017	BIO International Meeting	San Diego, US	Launching the 5 th edition of the Building the Bio Economy report
*56	February 2018	The U.S. Chamber of Commerce's International IP Index – Sixth Edition	Washington DC	Launching the 6th Edition on the International IP Index, US Chambers of Commerce
*57	6 March 2018	Towards a Sustainable European Market for Off Patent Biologics	European Parliament	Presentation of study findings
*58	June 2018	BIO International Meeting	Boston US	Launching the 6th edition of the Building the Bio Economy report
*59	November 2018	25th Annual Conference of the Irish Pharmaceutical Healthcare Association (IPHA)	Dublin	Keynote speaker
*60	Feb 2019	Mid Term review of the EIPIN-IS project	Maastricht Campus, Brussels	
*61	February 2019	The U.S. Chamber of Commerce's International IP Index – Sixth Edition	Washington DC	Launching the 7th Edition on the International IP Index, US Chambers of Commerce
*62	June 2019	BIO International Meeting	Philadelphia	Launching the 6th edition of the Building the Bio Economy report
*63	November 2019	CIP Net project	Nankai University (NKU), Tianjin, China	Public-private partnerships and technology exploitation
*64	December 2019	A joint project by the Karolinska Institute and Bayer Ag	Stockholm	The Global Life Sciences Innovation Race: Where Does Europe Stand? An Evidence-Based, Comparative Analysis of Europe's Attractiveness to Life Sciences Innovation Investment

b. Organization of Conferences or Sessions

	Date	Name of Conference	Place of Conference	Role
1	16.06.2005	The Lisbon Agenda and the Future of Information Technology and Intellectual Property Rights in Europe, a Joint Round Table of the Stockholm Network and Managing Intellectual Property Journal	Brussels, Belgium	Event Chairman & Co-Organizer
2	6.03.2006	Intellectual Property Frontiers - Intellectual Property Rights and Small & Medium-Sized Enterprises (SMEs): A Barrier to Innovation or an Engine for Growth? a joint workshop of the Stockholm Network and Managing Intellectual Property Magazine	Brussels, Belgium	Event Chairman & Co-Organizer
3	27.06.2006	A Stockholm-Network Workshop on Intellectual Property Rights, Competition Rules & Article 82: Is there a Sensible Middle Ground?	Brussels, Belgium	Event Chairman & Co-Organizer
4	25.10.2006	Intellectual Property Rights, Small and Medium Size Enterprises and Health - Related Public Private Partnerships: A joint workshop by the World Intellectual Property Organization Small and Medium-Sized Enterprises (SMEs) Division and the Stockholm Network	Geneva, Switzerland	Event Co-Chairman in collaboration with Mr. Guriqbal Singh Jaiya, Director, Small and Medium-Sized Enterprises (SMEs) Division, World Intellectual Property Organization (WIPO)
5	12.03.2008	Cost Pressures on the German Health System – Is Health Technology Assessment the Solution? A joint event by the Stockholm Network and the Institute for Free Enterprise	Berlin, Germany	Event Chairman & Co-Organizer

	Date	Name of Conference	Place of Conference	Role
6	14.03.2008	Are your Medicines Safe? – Counterfeits, Intellectual Property and the Future of Innovation, a joint workshop by the Stockholm Network and EVA (Finnish Business and Policy Forum)	Helsinki, Finland	Event Chairman & Co-Organizer
7	15.4.2008	The Process and Impact of the WHO Intergovernmental Working Group (IGWG) on Public Health, Innovation and Intellectual Property – An Assessment. A joint workshop by the Stockholm Network and the Maastricht University Faculty of Law	Maastricht, The Netherlands	Event Chairman & Co-Organizer
8	22.09.2008	Evidence-Based Policy in the Field of Intellectual Property Rights: Using Cutting-Edge Research to Improve Intellectual Property Policymaking – A joint workshop by the OECD and the Stockholm Network	Paris, France	Event Chairman & Co-Organizer
9	8.09.2009	Can Intellectual Property Rights Be Leveraged to Generate Greater Economic Value Among OECD Countries in a Period of Economic Crisis? A joint event by the Stockholm Network and MSD Israel	Ramat Gan, Kfar Hamacabia	Event Chairman & Co-Organizer
10	1.06.2010	Intellectual Property, Open Source, and Standards: Friends or Foes? Joint event by The Institute for Globalisation and International Regulation at Maastricht University Faculty of Law and the Stockholm Network Intellectual Property & Competition Programme	Brussels, Belgium	Co-Organizer & speaker
11	7.11.2010	Intellectual Property Rights, Foreign Direct Investment and Domestic Activities – Moving From a Zero Sum Game to a	Ankara, Turkey	Co-Organizer & speaker

	Date	Name of Conference	Place of Conference	Role
		Win-Win Model? A joint event by the Stockholm Network and MSD Israel		
12	17.06.2011	Standardizing the Standardization Process? What next for Intellectual, Property Rights, Competition and Innovation in Europe, co-organised by The Institute for Globalisation and International Regulation at Maastricht University Faculty of Law and the Stockholm Network Intellectual Property & Competition Programme	Maastricht, University, The Netherlands	Co-Organizer & speaker
13	18.10.2011	Roundtable: Is Ageing Good For Us? The Societal and Economic Effects of Ageing, organised by the Stockholm Network	Brussels	Event Chairman & Co-Organizer
14	21.06.2012	BIO International Meeting 2012, Workshop on Intellectual Property and Biotechnology - The Way Ahead	Boston, Mass	Event Chair & Co-Organizer
15	30 November 2012	Life Science Invest Russia – Panel on Harnessing the power of IP in Russia - Challenges and Opportunities	St Petersburg, Russia	Co-organizer & moderator
16	September 16 th 2013	Clinical Trials and Data Transparency – The Public Interest Case, a workshop organized by the Institute of Globalization and International Regulation (IGIR)	Brussels, Belgium	Event Chair & Co-Organizer
17	January 2015	European Intellectual Property Network Meeting	Maastricht, the Netherlands	Panel moderator and speaker
18	January 2016	US-India Business Council	Delhi, India	Keynote speaker: Building a Supportive Biopharmaceutical Environment in India

	Date	Name of Conference	Place of Conference	Role
19	March 2016	US-Indonesia Investment Initiative	Jakarta Indonesia	Keynote speaker: Building a Supportive Biopharmaceutical Environment in Indonesia

7. INVITED ADDRESSES

	Date of Conference	Name of Conference	Place of Conference	Subject of Lecture/Discussion/Comments
1	22.06.2005	Expert Dinner Debate, Patentability of Computer Implemented Inventions	Brussels, Belgium	Keynote Speaker , The Lisbon Strategy and the Future of Intellectual Property Policy- Making in Europe
2	12.07.2006	The Knesset's Science and Technology Committee – Special Session on Technology Transfer	The Knesset, Jerusalem, Israel	Keynote Speaker , Utilization and Transfer of Knowledge and Technologies Owned by Government and Public Bodies in Israel
3	04.06.2008	Stockholm Network Meeting of European Members of Parliament (MEPs)	Brussels, Belgium	Keynote Speaker , On Land, Knowledge and the Space in Between - Is There a Distinction Between Property Rights and Intellectual Property Rights
4	26.11.2008	Stockholm Network Meeting of European Policy Makers	Brussels, Belgium	Keynote Speaker , 'If It Ain't Broke, Don't Fix It' – Some Thoughts About Innovation
5	27.05.2009	The "Ortiada" in the Biotechnological track, the Israeli Sci-Tech School (Ort).	Kfar Saba, Israel	Keynote Speaker , The Biomedical Industry – From the Test Tube to the Market
6	8.06.2010	Bi-Annual Meeting of INTERPAT	New York, U.S	Keynote Speaker : the Political Economy of Pharmaceutical Intellectual Property battles in the 21st Century – on Companies, Trade Associations and Policy-Makers
7	3 November 2013	Montréal InVivo and Life Sciences Ontario Meetings	Montréal, Canada	Keynote Speaker : Canada's Intellectual Property Environment - Implications

	Date of Conference	Name of Conference	Place of Conference	Subject of Lecture/Discussion/Comments
		on the Competitiveness of Canada's Life Sciences		for Innovation and Growth in the Life Sciences Sector in Canada
8	28-29 April 2014	ABDI Workshop on: Building the Bioeconomy: Examining National Biotechnology Industry Development Strategies	Brasília & São Paulo, Brazil,	Keynote speaker: Examining National Biotechnology Industry Development Strategies
9	January 2016	US-India Business Council	Delhi, India	Keynote speaker: Building a Supportive Biopharmaceutical Environment in India
10	March 2016	US-Indonesia Investment Initiative	Jakarta Indonesia	Keynote speaker: Building a Supportive Biopharmaceutical Environment in Indonesia

8. COLLOQUIUM TALKS

	Date of Conference	Name of Conference	Place of Conference	Subject of Lecture/Discussion/Comments
1	15-16.05.2006	European Patent Office - Scenarios for the Future	Munich, Germany	Expert Speaker , the Economics of Patents
2	14.06.2006	Creation and Exploitation - Analysis of Sweden's Intellectual Property Performance	Stockholm, Sweden	Keynote Speaker , Analysis of Sweden's Intellectual Property Performance
3	4.12.2007	The Second Annual Conference of the Intellectual Property Forum of the Federation of the Israeli Chambers of Commerce	Tel-Aviv, Israel	Keynote Speaker , Intellectual Property Policy-Making in Israel – Reality and Vision
4	8.09.2008	European Patent Office Workshop	The Hague, the Netherlands	Keynote Speaker , Evidence Based Policy and the Patent System: How Can Patent Policy Benefit from Empirical Research
5	25.11.2008	The Future of Healthcare Reform in Slovenia - ? A	Ljubljana, Slovenia,	Keynote Speaker , Slovenian Healthcare

	Date of Conference	Name of Conference	Place of Conference	Subject of Lecture/Discussion/Comments
		Stockholm Network Event in Association with the Joze Pucnik Institute		Reform and the Prospects for Innovation
6	26.11.2008	Stockholm Network Meeting of European Policy Makers	Brussels, Belgium	Keynote Speaker , 'If It Ain't Broke, Don't Fix It' – Some Thoughts About Innovation
7	27.04.2010	Postgraduate Course in Intellectual Property Rights, IDEA CINA,	Milan, Italy	Keynote Speaker , Intellectual Property Rights, Technology Transfer and the Environment – Implications for Policy
8	27.02.2012	Patents and Trademarks Authority, Israel	Jerusalem, Israel	Keynote Speaker , Patents in the 21st Century – Is it time to replace the system, or is it more relevant than ever?
9.	17.10.2014	IGIR Experts Lectures	Maastricht, Holland	Keynote Speaker: What can Industry and Academia can learn from one another in the field of IP
10	26 March 2015	Joint meeting of the American Chamber of Commerce to the European Union	Brussels Belgium	The European Medicines Agency's Policy on the Public Release of Clinical Trials Data – One Year on
11	19 May 2016	Behihang University Seminar	Beijing, China	Policy, economics and knowledge creation in biomedical field - Considering China in a global context
*12	December 2019	A joint project by the Karolinska Institute and Bayer Ag	Stockholm	The Global Life Sciences Innovation Race: Where Does Europe Stand? An Evidence-Based,

	Date of Conference	Name of Conference	Place of Conference	Subject of Lecture/Discussion/Comments
				Comparative Analysis of Europe's Attractiveness to Life Sciences Innovation Investment

9. RESEARCH GRANTS AND FUNDED PROJECTS

Note - Research grants and funded projects - the grants below were provided by international institutions, private bodies and public institutions. Since my affiliation to the University is based on partial position (0.25 specialist positions) I have a limited procedural ability to apply to competitive and academic grants. As such the following grants were awarded to me on a personal and individual bases, i.e. not via the University. Nevertheless the grants below have undergone rigorous professional review, based on the criteria of each organization, recognizing research excellence, topical needs, international profile, and ability to deliver high quality results

Year	Granting Organization	Topic	Role	Amount
2003	Enterprise LSE, UK	Comparative research – comparing the intellectual property environments of Israel and Singapore (part of joint research team)	PI	US\$ 35,000
2004	United Nations University Conference on Comparative Research in Integration Studies, Brussels	Research on multilateral, regional and bilateral intellectual property trade agreements	PI	EUR 6,000
2004	The Gertner Institute, Israel	Management and exploitation of intellectual property rights in government- owned hospitals in Israel	PI	US\$ 15,000
2005	International Centre for Trade and Sustainable Development, Switzerland	Research on pharmaceutical data exclusivity	PI	US\$ 2,000
2006	Merck International Grants Committee, U.S.	The Intellectual Property Programme (Intellectual Property Academy)	PI	US\$ 25,000
2006	Timbro, Sweden	Assessment of Sweden's intellectual property environment	PI	EUR 6,000
2007	Merck International Grants Committee, U.S.	The intellectual property Programme (IP Academy)	PI	US\$ 25,000
2007	The European Centre for International Political Economy (ECIPE)	The US and EU's Approach to the International Regulation of	PI	EUR 5,000

		Intellectual Property Trade-Related Agreements		
2007	The IP Forum, The Federation of Israeli Chambers of Commerce	The Process of intellectual property policy-making in Israel – theory and practice	PI	\$US 9,000
2008	Scian, The Institute for Scientific Policy Analysis	Scian, The Institute for Scientific Policy Analysis	PI	US\$ 20,000
2008	European Patent Office	Economic aspects of the patent system	PI	EUR 5,000
2009	European Patent Office	Global survey of licensing activities in selected fields of Environmentally Sound Technologies (ESTs)	PI	EUR 12,000
2010	World Intellectual Property Organization (WIPO)	Study on the Role of Intellectual Property Rights in the Transfer of Environmentally Sensitive Technologies (ESTs)	PI	EUR 15,000
2011	Institute for Globalization and International Regulation, Maastricht University	Conducting the <u>economic</u> chapter of the external study on the Anti-Counterfeiting Trade Agreement (ACTA), commissioned by the Directorate General for External Studies, Policy Department of the European Parliament	PI	EUR 2,000
2012	Enterprise LSE (London School of Economics)	Intellectual property consultant to Enterprise LSE (London School of Economics), preparing a report to the European Parliament, Directorate General for External Policies on The Anti-Counterfeiting Trade Agreement (ACTA) and its impact on access to generic medicines	PI	EUR 4,000
2013	US Chamber of Commerce – Global Intellectual Property Center	Creation of the GIPC Intellectual Property Index	PI	\$US 5000
2013	US Chamber of Commerce	Creation of the Developing a Global Business Rule of Law “Dashboard	PI	\$US 5000
2014	BIO	Research: Building the Bioeconomy: Examining National Biotechnology Industry Development Strategies	PI	\$US 4000
2015	US Chamber of Commerce – Global Intellectual Property Center	Creation of the GIPC Intellectual Property Index – 3 rd edition	PI	\$US 5000

2016	BIO	Research: Building the Bioeconomy: Examining National Biotechnology Industry Development Strategies – 2 nd edition	PI	\$US 6000
2017	US Chamber of Commerce – Global Intellectual Property Center	Creation of the Developing a Global Business Rule of Law “Dashboard	PI	\$US 6000
2018	BIO	Creation of the GIPC Intellectual Property Index – 4 th edition	PI	\$US 6000

10 SCHOLARSHIPS AND AWARDS

Year	Granting Organization	Topic	
Scholarships			
2001	London School of Economics, UK	Grant for Ph.D.	
2004	Pfizer Pharmaceuticals Ltd, Israel	Pfizer's Public Health Policy Forum , School of Public Health University of Haifa, 150,000NIS	
2004	Pfizer Pharmaceuticals Ltd, Israel	Pfizer's Public Health Policy Forum , School of Public Health University of Haifa, 100,000 NIS	
2007	Pfizer Pharmaceuticals Ltd, Israel	Health 2010 Forum, School of Public Health University of Haifa 50,000 NIS	
2010	Pfizer Pharmaceuticals Ltd, Israel	Health 2010 Forum, School of Public Health University of Haifa, 50,000 NIS	
2011	Pfizer Pharmaceuticals Ltd, Israel	Pfizer's Public Health Policy Forum , School of Public Health University of Haifa, 50,000 NIS	
2012	Pfizer Pharmaceuticals Ltd, Israel	Pfizer's Public Health Policy Forum , School of Public Health University of Haifa, 50,000 NIS	
*2013	Pfizer Pharmaceuticals Ltd, Israel	Pfizer's Public Health Policy Forum , School of Public Health University of Haifa, 50,000 NIS	

11. TEACHING

A. Courses Taught in Recent Years

Title	Institution	Year	Type	Level	Number of Students (average)
Bioethics and Intellectual Property (Guest lecturer)	Faculty of Health Sciences, Ben-Gurion University	2003 - 2005	Course	Post-graduate students (M.A. and Ph.D)	25
The International Political Economy of Trade Policy	Hebrew University, Department of International Relations	2005	Course	B.A. Students	60
Management and exploitation of IPRs in the International Arena	Hebrew University, Department of International Relations	2006	Course	B.A. and post-graduate students	40
Management and Exploitation of Knowledge Assets and Intellectual Property Rights	University of Haifa, School of Public Health	2003 to date	Course	Post-graduate students	30
Biomedical Entrepreneurship	University of Haifa, School of Public Health	2004 to date	Course	Post-graduate students	15
Political Economy of Public Health Policy in Israel	University of Haifa, School of Public Health	2006 to date	Course	Post-graduate students	30
Introduction to Intellectual Property Rights in Biomedicine	Faculty of Health Sciences, Division of Basic Science, Ben-Gurion University	2009 - 2011	Course	Post-graduate students	20-25
Planning, Managing and Executing Clinical Trials (Introduction to Clinical Trials) (co-moderator)	Faculty of Health Sciences, Division of Basic Science, Ben-Gurion University	2009 - 2011	Course	Post-graduate students	20-25
Seminar – biomedicine, Economics, Regulation, Ethics and the Interactions Between Them	Faculty of Health Sciences, Division of Basic Science, Ben-Gurion University	2009 - 2011	Course	Post-graduate students	20-25
Introduction to Entrepreneurship, Management, and Implementation of Bioechnological Projects: From the Test-Tube to the Market.	Faculty of Health Sciences, Division of Basic Science, Ben-Gurion University	2010 - 2011	Course	Post-graduate students	20-25

Commercialization and Utilization of Biomedical Knowledge Assets – an Introduction to the World of Tech Transfer	Faculty of Health Sciences, Division of Basic Science, Ben-Gurion University	2010 - 2011	Course	Post-graduate students	10
Technology Transfer and Franchising Law	Masters Intellectual Property Law and Knowledge Management (LLM/MSc, Maastricht University Faculty of Law	2010 to date	Module	Post-graduate students	15
Legal English and Methodology – Understanding basic economic dilemmas and perspectives relating to the use of IPRs, applying different models of economic analysis, collecting and analyzing economic data	Masters Intellectual Property Law and Knowledge Management (LLM/MSc, Maastricht University Faculty of Law	2015 to date	Module	Post-graduate students	15
<ul style="list-style-type: none"> Principles and dilemmas in management 	University of Haifa, School of Public Health	2020 to date	Course	Post-graduate students	50

B. Supervision of Graduate Students

Degree	Title of Thesis	Name of Student	Date of Completion/ in Progress
*Ph.D.	Trademarks and the margins of dilution	Amir Fridman	In progress
*Ph.D.	Patent pools and biomedical R&D	Rachel Chu	In progress
*Ph.D.	Standardization, patent pools and competition policy	Math Heckman	Completed 2017
*PhD	Patents quality in pharmaceuticals	Nana	In progress

II. PUBLICATIONS

Note: For joint publications the authors have contributed equally, unless otherwise specified.

A. Ph.D. Dissertation

The International Political Economy of Intellectual Property Rights - the TRIPS Agreement and the Advanced Pharmaceutical Industry in Europe, May 2002.

Field of research: The international political economy of intellectual property rights. As a case study the research takes the latest agreement on trade-related aspects of intellectual property rights (TRIPs) of the WTO and relates it to the advanced, research-based, pharmaceutical industry in Europe. It explores how the latter organises and operates both domestically and internationally, in order to secure its interests with regard to the international intellectual property agenda. The thesis combines economic aspects (trade and technology-related issues as well as applied economics and statistical analysis) within a 'North-South' political framework.

Supervisors: Dr. Brian Hindley, Reader (Emeritus), Department of Economics, London School of Economics

Dr. Razeen Sally, Senior Lecturer, Department of International Relations, London School of Economics

Number of pages: 340

(Written in English)

The thesis was published as a book (see under authored books)

B. Scientific Books (Refereed)

Authored Books – Published

1. **Pugatch, M.P.** *The International Political Economy of Intellectual Property Rights* (Edward Elgar: Cheltenham, UK, June 2004) 284 p. [based on PhD dissertation] – [Cited by 120 scholars based on Google Scholar]

Authored Books - Under Contract – see work in preparation

Edited Books and Special Journal Issues - Published

1. **Pugatch, M.P.**, ed. *The Intellectual Property Debate: Perspectives from Law, Economics and Political Economy* (Edward Elgar: Cheltenham, UK, September 2006), 374 p. Cited by 31 authors based on Google Scholar
2. **Pugatch, M.P.**, Jensen, A. eds. *Healthy IPRs - A Forward Look at Intellectual Property* (Stockholm-Network: London, April 2007), 192 p.

C. Monographs

Monographs are scientific publications that focus integrating academic expertise with concrete policy implications. They are published by esteemed, recognized think-tanks and research centers.

Edited

1. Jensen, A. **Pugatch, M.P.**, (eds). *Intellectual Property Frontiers – Expanding the Borders of Discussion* (Stockholm Network: London, December 2005), 56 p.

Authored

2. **Pugatch, M.P.** *Beyond Lisbon – Reviewing EU Policies on IP, Competition and Innovation* (Stockholm-Network: London, 2007), 24 p.
3. **Pugatch, M.P.** *A Transatlantic Divide? The US and EU's Approach to the International Regulation of Intellectual Property Trade-Related Agreements* (European Centre of International Political Economy: Brussels, April 2007), 30 p.
4. **Pugatch, M.P.**, Ficaï F. "A Healthy Market – An Introduction to Health Technology Assessment" (Stockholm-Network: London, April 2007) [*authors appear according to their relative contribution], 9 p.
5. Jensen, A. Moore, S., **Pugatch M.P.** *Why Digital Rights Management?*, Stockholm-Network Intellectual Property and Competition Policy Papers (paper number 6) (London: April 2007), 10 p.
6. **Pugatch, M. P.**, Davison, H. *A Healthy Market? Health Technology Assessment in Context* (Stockholm-Network: London, July 2007) [*authors appear according to their relative contribution], 19 p.
7. Torstensson, D., Sasaki, R., **Pugatch, M. P.** *Free Use or Fair Use? The Role of Internet Mediators in Protecting Intellectual Property Rights* (Stockholm-Network: London, October 2007), 41 p.

8. Niemietz, K., **Pugatch, M. P.** *Health Technology Assessment in the UK and Germany* (Stockholm-Network: London, October 2007), 32 p.
9. Argov, R., Davison, H, **Pugatch M. P.** *Promoting Technology Transfer in Developing Countries: Lessons from Public-Private Partnerships in the Field of Pharmaceuticals.* Stockholm-Network Experts' Series on Pharmaceutical IPRs, paper no. 1 (Stockholm Network: London, December 2007), 31 p.
10. Torstensson D., **Pugatch, M. P.** *Courting Confusion? Where is Canada's Intellectual Property Policy Heading?* Stockholm-Network Experts Series on Pharmaceutical IPRs, paper no 3. (Stockholm-Network: London, 2008), 40 p.
11. **Pugatch, M. P.** *If it Ain't Broke, Don't Fix It - A Discussion Paper on the Benefits of the Voluntary Market-Driven Approach to Innovation* (Stockholm-Network: London, 2008), 46 p.
12. Healy P., **Pugatch, M. P.** *Theory versus Practice: Discussing the Governance of Health Technology Assessment Systems* (Stockholm-Network: London, 2009), 63 p.
13. Torstensson D., **Pugatch, M. P.** *Europe's 'Postcode Lottery' – the Challenge of Central authorisation Versus National Access to Medicines* (Stockholm-Network: London, 2009), 19 p.
14. Chu R, **Pugatch, M. P.** *Biosimilars or Biogenerics – Discussing the Present, Considering the Future* (Stockholm-Network: London, October 2009), 31 p.
15. Torstensson D., **Pugatch, M.P.** *Keeping Medicines Safe - A Study of the Regulations Guiding the Approval of Medicines in Emerging Markets* (Stockholm-Network: London, 2010), 56 p, Cited by 9 authors based on Google Scholar
16. Chu, R. Torstensson D., **Pugatch, M.P.** *Patient Safety and Comfort: the Challenges of Switching Medicines* (Stockholm-Network: London, 2010), 57 p.
17. **Pugatch, M.P.**, Torstensson, D. *Underneath the Surface - Pharmaceutical Procurement Processes and Their Role in the Distribution of Substandard and Counterfeit Medicines in Emerging Markets* (Stockholm-Network: London, 2012), 83 p.
18. Healy P., **Pugatch, M. P.** *Capturing Value - Why Dynamic Efficiency Should be Considered in the Pricing and Reimbursement of Medicines* (Stockholm-Network: London, 2012), 83 p.
19. **Pugatch, M.P.**, Johnston A, Taylor D. *Clinical Trials and Data Transparency the Public Interest Case* (September 2013, a Pugatch Consilium report, commissioned by PhRMA and EFPIA)
20. **Pugatch, M.P.**, Disney H, *Innovative Future, Scenario Analysis of Pharmaceutical Innovation and Access to Medicines in Europe* (February 2014, a Pugatch Consilium report, commissioned by EFPIA)

21. **Pugatch, M.P.**, Torstensson, D., Chu R. *The Value of Cross-Border Data, The Value of Cross-Border Data to Consumers, Companies and Governments* (April 2014, Pugatch Consilium report, commissioned by CEO Technology Council)
22. **Pugatch, M.P.**, Torstensson, D. *Building the Bio-Economy Examining National Biotechnology Industry Development Strategies* (May 2014, Pugatch Consilium report, commissioned by BIO)
23. **Pugatch, M.P.**, Torstensson, D. *Building the Bio-Economy Examining National Biotechnology Industry Development Strategies - 2n edition* (June 2015, Pugatch Consilium report, commissioned by BIO)
25. **Pugatch, M.P.**, *The Next Frontier in Ensuring the Quality of Medicines Maintaining International Quality and Safety Standards in the Manufacturing and Supply of Active Pharmaceutical Ingredients 2015*, Pugatch Consilium report, commissioned by PhRMA)
26. **Pugatch, M.P.**, Torestenssen, D, Chu R. *Biopharmaceutical Competitiveness & Investment 2015 – 2nd edition* (Washington DC)
27. **Pugatch, M.P.**, Torestenssen, D, Chu R, *The U.S. Chamber International IP Index, Infinite Possibilities, Fourth Edition* (February 2016, Washington DC)
28. **Pugatch, M.P.**, *A Global assessment of Localization Policies and Incentivizing Life Science Investment and Innovation* (March 2016, Washington DC)
29. **Pugatch, M.P.**, Torestenssen,, Laufer, M. *Challenges and Opportunities – Developing the Biotechnology Sector in Colombia* (July 2016, Washington DC)
30. **Pugatch, M.P.**, Torestenssen, D, Chu R, *The U.S. Chamber International IP Index, The Roots of Innovation, Fifth Edition* (February 2017, Washington DC)
31. **Pugatch, M.P.**, *Charting the Course to Sustainable Neglected Disease Globally* (Pugatch Consilium: May 2017)
- *32. **Pugatch, M.P.**, Torestenssen, Laufer, M. *UNINTENDED CONSEQUENCES How introducing a manufacturing and export exemption to supplementary protection certificates would weaken global standards of IP protection and result in direct losses to Europe’s research-based biopharmaceutical industry* (September 2018, Brussels)
- *33 **Pugatch, M.P.**, Torestenssen, D, Chu R, *The U.S. Chamber International IP Index, Sixth Edition* (February 2018, Washington DC)
- *34 **Pugatch, M.P.**, Torestenssen, Laufer, M. *Towards a sustainable European Market for Off-Patent Biologics* (March 2018, Brussels)
- *35. **Pugatch, M.P.**, Torestenssen, D *Building the Bio Economy, 5th Edition* (June 2018, Washington DC)

*36 **Pugatch, M.P.**, Torestenssen, D. U.S. Chamber International IP Index, Sixth Edition (February 2019, Washington DC)

*37 **Pugatch, M.P.**, Evaluating the Orphan Regulation and its impact on patients and rare disease R&D in the European Union (Brussels, March 2019)

*38 **Pugatch, M.P.**, Torstensson, D. Building the Bio-Economy Examining National Biotechnology Industry Development Strategies – 6th edition (June 2019, Pugatch Consilium report, commissioned by BIO)

*39 **Pugatch, M.P., 2019** Biopharmaceutical Competitiveness & Investment (BCI) Survey - Emerging Markets, November 2019, Pugatch Consilium report, commissioned by BIO)

D. Articles in Refereed Journals

1. **Pugatch, M. P.** (2005). Patents, Pharmaceuticals and the Implementation of Paragraph 6 of the Doha Declaration on the TRIPs Agreement and Public Health. *Journal of BioLaw and Business*, 8 (1). 16-21.

SJR (2005)=0.117; R=139/158 (Q4) in Biotechnology, 69/75 (Q4) in Applied Microbiology and Biotechnology, 312/364 (Q4) in Public Health, Environmental and Occupational Health

2. **Pugatch M.P.** (2005). The International Regulation of IPRs in a TRIPs and TRIPs *plus* World. *Journal of World Investment and Trade*, 6 (1). 430-465.

W&L Law Journal Rankings (2008): 65/93 Commercial Law (Q3)

3. Von Braun, J., & **Pugatch, M.P.** (2005). The Changing Face of the Pharmaceutical Industry and Intellectual Property Rights. *Journal of World Intellectual Property*, 8 (5). 599-623. Cited by 18 authors based on Google Scholar

SJR (2005)=0.104; R=216/275 (Q4) in Law

W&L Law Journal Rankings (2005): 35/51 in Intellectual Property (Q3)

4. **Pugatch M.P.** (2006). Political Economy of Intellectual Property Policy-Making: Theory and Practice. *Journal of World Investment and Trade*, 7 (2) . 257-274., Cited by 9 authors based on Google Scholar

W&L Law Journal Rankings (2008): 65/93 Commercial Law (Q3)

4a. **Pugatch, M.P.** (2006). Political Economy of Intellectual Property Policy-Making: Theory and Practice. *The Geneva Post Quarterly*, 1 (2). 161-192.

5. **Pugatch, M.P.** (2006). Measuring the Strength of National Pharmaceutical Intellectual Property Regimes: Creating a New Pharmaceutical IP Index. *Journal of World Intellectual Property*, 9 (4). 373-391, Cited by 11 authors based on Google Scholar

SJR (2006)=0.107; R=231/301 (Q4) in Law

W&L Law Journal Rankings (2006): 37/54 in Intellectual Property (Q3)

6. **Pugatch, M.P.** (2007). Measuring the Strength of National Pharmaceutical Intellectual Property Regimes in Eight Countries: Using a Pharmaceutical IP Index to Benchmark India. *Journal of World Investment and Trade*. 8 (4). 573-591.

W&L Law Journal Rankings (2008): 65/93 in Commercial Law (Q3)

7. **Pugatch, M.P.**, & Disney, H. (2008). Intellectual Property, Innovation and Consumers – An Alliance for Good. *European Journal of Consumer Law*, 4. 453-452. [*authors appear according to their relative contribution]

8. **Pugatch, M.P.** (2009). The Process of Intellectual Property Policy-Making in 21st Century – Shifting from General-Welfare Model to a Multi-Dimensional One. *The European Intellectual Property Review*, 6. 307-314.

W&L Law Journal Rankings (2009): 50/65 in Intellectual Property (Q4)

9. **Pugatch, M. P.** (2010). Encouraging the Technology Transfer of Environmentally Sound Technologies (ESTs): Reducing Risks in the Transfer and Utilization of ESTs to Mitigate Climate Change. *European Journal of Risk Regulation* (EJRR), 1(4). 408-415

SJR (2011)=0.211; R=25/63 (Q2) in Safety Research

10. **Pugatch, M. P.** and Chu, R. (2011). The strength of Pharmaceutical IPRs vis- à -vis Foreign Direct Investment in Clinical Research: Preliminary Findings. *Journal of Commercial Biotechnology* [*authors appear according to their relative contribution], 4(17). 11p, Cited by 9 authors based on Google Scholar

SJR (2011)=0.216; R=164/260 (Q3) in Biotechnology, 114/209 (Q3) in Management of Technology and Innovation, 362/532 (Q3) in Economics and Econometrics

11. **Pugatch, M. P.** (2011). Patent Pools and Collaborative Initiatives: Assessing the Efficacy of Alternative Models to Intellectual Property in Terms of the Ability to Develop New Medicines, Especially for Neglected Diseases – an Empirical Analysis. *European Journal of Risk Regulation* (EJRR), 4(4). 566-571.

SJR (2011)=0.211; R=25/63 (Q2) in Safety Research

W&L Law Journal Rankings (2011): 9/14 (Q3) in Administrative Law, 43/69 (Q3) in Environment, Natural Resources and Land Use, 10/37 (Q2) in European Law, 32/45 (Q3) in Health, Medicine, Psychology and Psychiatry, 36/50 (Q3) in Science, Technology and Computing

12. **Pugatch, M. P.** (2011). Intellectual Property Policy Making in the 21st Century, *The WIPO Journal*, 3(1), 71-80

*13. **Pugatch, M.P.**, Chu, R., Torstensson, D. & Dayan, A. (2012), “Does your country deserve investment from biopharma?” *Scientific American World* (2012, p.85)

E. Articles or Chapters in Scientific Books (which are not Conference Proceedings)

1. **Pugatch, M.P.** "Controversy Over Intellectual Property Rights and Access to Medicines", in: *Issues in Health Sector Reform 2003/2004* (London: Commonwealth Business Council, October 2003), pp. 76-79

2. **Pugatch, M.P.** 'What Does the Deal on Drugs Patents Aim to Achieve?', in: *Africa After Cancun: Trade Negotiations in Uncertain Times*, The South African Institute for International Affairs, Trade Report No. 2, pp. 31-41 (SIIA, December 2003)

3. **Pugatch M.P.** "Much Ado About Nothing - the WTO TRIPs Deal on Drugs' Patents", in: Debroy, B., Saqib, M. and Mitra, M. ed. *WTO at Ten: Looking Back to Look Beyond* (Konark Publishers: New Delhi, February 2005), vol.2, Chapter 11, pp. 333-347

4. **Pugatch M.P.** "Data Exclusivity: Implications for Developing Countries", Bridges, vol. 9: no.6-7 (July 2005: 21-22), pp. 21-22. <http://www.ictsd.org/monthly/bridges/BRIDGES9-6-7.pdf>

5. **Pugatch, M.P.** "What is the Value of Your Patent? Theory, Myth and Reality", in: Jensen, A. Pugatch, M.P., (eds). *Intellectual Property Frontiers – Expanding the Borders of Discussion* (Stockholm Network: London, December 2005), pp. 34-35

6. **Pugatch, M.P.** "Resurrecting the TRIPs Agreement", in: Jensen, A. Pugatch, M.P., (eds). *Intellectual Property Frontiers – Expanding the Borders of Discussion* (Stockholm Network: London, December 2005), pp 34-35

7. **Pugatch, M.P.** "The International Regulation of IPRs in a TRIPs and TRIPs Plus World", in: Woolcock, S.B. (ed.) *Trade and Investment Rule-Making: the Role of Regional and Bilateral Agreements* (United Nations University Press: New York, 2006), pp. 177-207, Cited by 17 authors based on Google Scholar

8. **Pugatch, M. P.** "Intellectual Property and Pharmaceutical Data Exclusivity in the Context of Innovation and Market Access", in: Vivas-Eugui, D. Tansey, G. and Roffe, P. (eds.) *Negotiating Health* (Earthscan & International Centre for Trade and Sustainable Development: Geneva, February 2006), pp. 97-132, Cited by 31 authors based on Google Scholar

9. **Pugatch, M. P.** "Political Economy of Intellectual Property Policy-Making: Theory and Practice - An Observation from a Realistic (and Slightly Cynical) Perspective, in: Macmillan F. (ed) *New Directions in Copyright Law. Volume 5* (Edward Elgar: Cheltenham, UK and Northampton, MA, USA, 2007), pp. 95-118

10. **Pugatch, M.P.** Zlotnick, O. Teubal, M. "Israel's High Tech Catch-Up Process: The Role of IPR and Other Policies" in Odagiri, H. Goto, A. Sunami, A and Nelson, R. (eds). *Intellectual Property Rights and Catch-Up: An International Comparative Study* (Oxford University Press, 2010), chapter 7, Cited by 90 authors based on Google Scholar

11. **Pugatch, M. P.** "Trade Related Intellectual Property Rights", in :Woolcock S., Heydon, K. (eds) in: *Ashgate Research Companion to International Trade* (publication due in July 2012), 20 p.

12. Kamperman S, A. Pugatch, M.P. in Jolly, A (ed), *European Capacity for Innovation”, The Handbook of European Intellectual Property, 4th Edition*, (2015, Kogan Page, London)

Accepted for Publication

13. Pugatch, M.P Regulatory Data Protection for Pharmaceuticals – State of Play, Contributed Chapter for the EIPIN 2016 Meeting in Munich (Oct 2020)

F. Articles in Conference Proceedings

1. **Pugatch M.P.** *Intellectual Property and Pharmaceutical Data Exclusivity in the Context of Innovation and Market Access*, prepared for the International Centre for Trade and Sustainable Development: the Third Bellagio Dialogue on Development and Intellectual Property (Geneva: UNCTAD- ICTDS: October 2004), 24 p.

2. **Pugatch. M.P.** *Political Economy of Intellectual Property Policy-Making: Theory and Practice*, paper presented at the AHRC Copyright Research Council 2006 Workshop: Copyright, Corporate Power and Human Rights (London: January 2006) [see item in section D.9.], 19 p.

3. **Pugatch, M.P.**, Torstensson. D. "The Good, the Bad, and the Ugly – How have Policymakers Dealt with the Growing Complexity of the Intellectual Property Debate and the issue of Online Piracy?", *Conference Board of Canada, The International Forum on The Creative Economy*, Compendium of Research Papers (Ottawa: August 2008), 10 p.

4. **Pugatch, M. P.**, Zlotnick, O. Teubal, M. *Israel's High Tech Catch-Up Process: The Role of IPR and Other Policies*, paper presented at the 4th Annual Conference of the EPIP Association (University of Bologna, Bologna, Italy, September 24-25, 2009), 37 p.

G. Entries in Encyclopedias

None

H. Other Scientific Publications

Reports

1. **Pugatch M.P.** *Implications of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) for Bangladesh*, Background Study to the Government of Bangladesh, prepared for Maxwell Stamp plc, (London: October 1999), 26p.

2. **Pugatch M.P.** *WTO Seattle Negotiating Issues and Positions*, Working Paper for the Government of Bangladesh, prepared for Maxwell Stamp plc, (London: November 1999), 11p.

3. **Pugatch, M.P.** *WTO Agreement on Agriculture: Background Paper*, prepared for the Israeli Vegetable Board, (September 2000) (in Hebrew), 10p.

4. **Pugatch, M.P.** *WTO Agreement on Agriculture: Data from the WTO Suggests that Developed Countries, Notably the U.S. and the EU, Have Increased their Usage of 'Green-Box' and 'Blue Box' Support*, prepared for the Israeli Vegetable Board (September 2000) (in Hebrew) 3p.

5. **Pugatch, M.P.** *Market Access under the WTO Agreement on Agriculture: The Israeli Case of Imported Frozen Potatoes*, prepared for the Israeli Vegetable Board, (November 2000), (in Hebrew) 8p.
6. **Pugatch, M.P.** *Organising, Strengthening and Exploiting Intellectual Property Assets by the Agricultural Boards in Israel*", prepared for the Israeli Egg and Poultry, Fruit, and Vegetable Boards, (November 2000), (in Hebrew), 14p.
7. **Pugatch M.P.** *Intellectual Property Rights in Public Research Organizations*, prepared for the Israeli Treasury Office (Jerusalem: December 2002), (in Hebrew), 12p.
8. **Pugatch M.P.** *The Value of Data Exclusivity: Implications for Israel's Economy, Social Welfare and Health*, prepared for Pharma-Israel (November 2003), 19p.
9. **Pugatch, M.P.** *Management and Exploitation of Intellectual Property Rights in Government- owned Hospitals in Israel*, prepared for the Gertner Institute, (in Hebrew) (February 2005), 67p.
10. Sen. J., Sally, R., **Pugatch, M.P.** *Intellectual Property Policy Fundamentals Supportive of the Pharmaceutical and Biomedical Industries in Advanced Developing Countries with Established R&D Capabilities*, Prepared for Enterprise LSE (London: March 2005), 25p.
12. **Pugatch, M.P.** *Creation and Exploitation - Analysis of Sweden's Intellectual Property Performance* (TIMBRO: Sweden, June 2006), 30p.
13. **Pugatch, M.P.** *Damage Assessment of Delays in the Examination and Approval of Patent Applications by the Patent and Trademark Office in Israel*, Report Commissioned by the Ministry of Justice- Patent and Trademark Office July 2006), (in Hebrew), 39p.
14. **Pugatch, M.P.** *Policy Making of Pharmaceutical Intellectual Property Rights in Israel – Reality and Vision*. Report Prepared to the IP Forum, Federation of Israeli Chambers of Commerce (ICC Israel: Tel-Aviv, November 2007), (in Hebrew) 84p.
15. **Pugatch, M.P.** *Survey of Licensing Activities in Selected Fields of Environmentally Sound Technologies (ESTs)*, Submitted to the United Nations Environment Programme (UNEP), the European Patent Office (EPO), and the International Centre for Trade and Sustainable Development (ICTSD) (January 2010), 44p.
16. Chu, R. **Pugatch, M.P.** Submission to the European Commission Guidelines on the Applicability of Article 101 of the Treaty on the Functioning of the European Union to Horizontal Co-operation Agreements (Stockholm-Network: London, 2010), 10p.
17. **Pugatch, M. P.** *The Role of Intellectual Property Rights in the Transfer of Environmentally Sensitive Technologies (ESTs)*, Report Prepared to the Global Challenges Division, World Intellectual Property Organization (WIPO: Geneva, July 2010), 41p.
18. **Pugatch, M. P.** Overall Economic and Commercial Assessment of Anti-Counterfeiting Trade Agreement (ACTA), in *Anti-Counterfeiting Trade Agreement an Assessment Report*,

Prepared by the Institute for Globalization and International Regulation, Maastricht University; Commissioned by the Directorate General for External Policies of the Union (European Parliament, July 2011), pp. 32-47

19. **Pugatch, M.P.**, Torstensson, D. *The impact of the Anti-Counterfeiting Trade Agreement (ACTA) on Access to Medicines in Developing Countries*, Report Submitted to Enterprise LSE as part of a workshop of the European Parliament, Directorate General for External Policies on The Anti-Counterfeiting Trade Agreement (ACTA) (June 2012), 19 p.

20. Torstensson, D., **Pugatch, M.P** (2013) INDIA: International Outlier on IP A Review of India's Relationship with Intellectual Property Rights and Its Economic Consequences, (Global Intellectual Property Center, US Chamber of Commerce, July 2013)

21 **Pugatch, M.P.**, Chu, R., Torstensson, D. *Charting the Course - GIPC International IP Index* (2nd edition), (January 2014, US Chamber of Commerce)

22. **Pugatch, M.P.**, Torstensson, D., Chu R. *The Value of Cross-Border Data, The Value of Cross-Border Data to Consumers, Companies and Governments* (April 2014, Pugatch Consilium report, commissioned by CEO Technology Council)

23. **Pugatch, M.P**, Torestenssen, D, Chu R, The Creative Industries and the BRICS (September 2014, CISAC, Paris)

24. Pugatch, M.P, The Next Frontier in Ensuring the Quality of Medicines Maintaining International Quality and Safety Standards in the Manufacturing and Supply of Active Pharmaceutical Ingredients 2015, Pugatch Consilium report, commissioned by PhRMA)

25. Pugatch, M.P, Torestenssen, D, Chu R. Biopharmaceutical Competitiveness & Investment 2015 – 2nd edition (Washington DC)

26. Pugatch, M.P, Torestenssen, D, Chu R, The U.S. Chamber International IP Index, Infinite Possibilities, Fourth Edition (February 2016, Washington DC)

Legislation

1. **Pugatch, M.P.** *Model Bill: Utilization and Transfer of Knowledge and Technologies Owned by Government and Public Bodies in Israel*, prepared for the Member of the Knesset, MK Meli Polishook Bloch, Chairman of the Science and Technology Committee, (in Hebrew), (July 2004), 23p.

I Professional Magazines and Bulletins

1. **Pugatch, M.P.**, Shani S (alphabetical order). "Direct to Consumer Advertising in Prescription Drugs (DTCA)", in: *Pharmaline Israel* (August 2002), (in Hebrew), pp. 14, 22

2. **Pugatch, M.P.** 'Data Exclusivity in the Context of EU Enlargement', in: *IPR Bulletin*, no. 12 (December 2003 - January 2004), pp. 10-15

3. **Pugatch, M.P.** 'What is the Value of Your Patents? Theory, Myths and Realities", in: *IPR Bulletin*, no.17 (October-November 2004), pp. 2-3
4. **Pugatch M.P.** "It is not the Technology, Stupid" in: *Managing Intellectual Property*, issue. No. 148 (London: April 2005)
5. **Pugatch, M.P.** "A New Way to Measure Success in the IT Industry: a Project Organized Jointly by MIP, the Stockholm Network and the Progress & Freedom Foundation to Assess the Level of IP Protection Available for the IT Industry in the World's Major Markets", *Managing Intellectual Property Magazine*, (London: July-August 2006)
6. **Pugatch, M.P.** "Big Pharma Strikes Back", in: *Pharmaceutical Executive Europe* (September 2006), p.70
7. **Pugatch, M.P.** "Index Reveals EU's IT Innovation Deficit - A new Index Measures the Strength of IP Protection for the IT Industry in 10 Key Markets", in: *Managing Intellectual Property Magazine* (London: December 2006), pp. 25-29
8. **Pugatch, M.P.** "Measuring the Strength of National Pharmaceutical Intellectual Property Regimes in Eight Countries: Using a Pharmaceutical IP Index to Benchmark India", *Intellectual Capital*, issue no. 24 (India, January-March 2008)
9. **Pugatch, M.P.** "Measuring IP Protection in the IT Sector" *Managing Intellectual Property Magazine* (London: July 2009)
10. **Pugatch, M.P.** "Intellectual Property Rights in Government Owned Hospitals in Israel – A Missed Opportunity", *Current events, Ideas and Information* – Special Issue Prepared for the Annual Meeting of the Organization of Government-Employed Physicians in Israel (June 2009), pp. 32-37
11. **Pugatch, M.P.** "Reflections – Genes for Sale?", *Scientific American Israel*, (September 2010)
- 12 **Pugatch, M.P.** "Standardizing the Standardization Process" *Managing Intellectual Property Magazine* (London: February 2012)
13. **Pugatch MP.** Stemmet, J. *South Africa's Intellectual Property Developments – Heading in the Wrong Direction?* (Sep 2014, FDI Magazine)
- *14. **Pugatch, M.P.**, Scientific American World View – Israel (June 2016)
<http://www.saworldview.com/scorecard/worldviewguide/#Israel>
- *15. **Pugatch, M.P.**, , Chu, R, To get India's Clinical Research Sector Live and Kicking, Again (The Hindu Business Line, 23 December 2016)
<http://www.thehindubusinessline.com/specials/pulse/invitation/article9442207.ece>
- *16. **Pugatch, M.P.** Forces Localization Fails to Deliver, *The Catalyst* (June 2016)
<http://catalyst.phrma.org/forced-pharmaceutical-localization-fails-to-deliver>

I. Other Publications

1. **Pugatch M.P.** "The Paradox of Intellectual Property Rights: Israel is Not Ready to Deal With the Implications of this Important and Vital Subject on its Economy", in: *The Exporter* (in Hebrew) (September 1999)
2. **Pugatch M.P.** "South Africa's Red Light: the Latest Compromise Between South Africa and the US on Aids Medicines Should Make Israel Worry", in: *Haaretz* (in Hebrew) (26 September 1999)
3. **Pugatch M.P.** "And the Rest Is Forgotten: Why is it Important for Israel to Deal With Intellectual Property Issues Other Than Copyrights?", in: *Haaretz* (in Hebrew) (8 November 1999)
4. **Pugatch M.P.** "Profits or Health? Israel Must Adopt a Policy of Parallel Imports in Patented Pharmaceuticals In Light of the Latest WTO Ruling Regarding the Patent Protection Dispute Between Canada and the European Community", in: *Haaretz* (in Hebrew) (27 April 2000)
5. **Pugatch M.P.** "United for Patients' Health? Instead of Fighting AIDS, Governments and Pharmaceutical Manufacturers Fight Each Other", in: *Haaretz* (in Hebrew) (23 July 2000)
6. **Pugatch M.P.** "Who Benefits From Parallel Imports?" in: *Haaretz - Health* (in Hebrew), (1 January 2001), Letters
7. **Pugatch M.P.** "Trade Ethics", in: *Haaretz - Health* (in Hebrew) (29 January 2001), Letters
8. **Pugatch M.P.** "Patenting Life", in: *Haaretz - Health* (in Hebrew) (24 September 2001)
9. **Pugatch M.P.** "Genetic Banks", in: *Haaretz - Health* (in Hebrew) (25 February 2002)
10. **Pugatch, M.P.** "Direct to Consumer Advertising in Prescription Drugs - Information to Consumers or Profits for Manufacturers", in: *Haaretz - Health* (in Hebrew) (26 August 2002)
11. **Pugatch, M.P.** "Software is Like any Other Inventive Activity", in *Financial Times*, Letters (9 February 2005)
12. **Pugatch, M.P.** "Going In the Wrong Direction", in: *Foreign Direct Investment Magazine* (London, June/July 2006), pp. 70-71
13. **Pugatch, M.P.** "the Breakaway Path – on the Latest Decisions of the Israeli Parliament on the Reimbursement of Medicines", in: NRG Portal www.nrg.co.il (in Hebrew) (25 December 2007)

14. **Pugatch, M.P.** "If It Ain't Broke, Don't Fix It: Some Thoughts about Innovation", *Foreign Direct Investment Magazine* (London, December 2008/January 2009)
- 15 Disney, H and **Pugatch, M.P** "Keeping Pirates at Bay", *European Voice* (3 March 2009),
16. **Pugatch, M.P.** "Is Public Sector Innovation Possible?" *Public Service Europe* (1 June 2011)
- *17. **Pugatch, M.P** "On Intellectual Property, a New Strategy", *The Indian Express*, (17 March 2014)
- *18. **Pugatch, M.P** "Towards a Positive IP Mindset", *The Hindu Business Line*, (29 April 2015)

Other Works Connected with my Scholarly Field -

1. European Patent Forum, Scenarios for the Future - Detailed Interviews – Written Interview with Dr. Meir Perez Pugatch (EPO: Munich, April 2007), pp. 535-540, <http://www.epo.org/news-issues/issues/scenarios/interviews/detailed.html>

J. Submitted Publications – not at the moment

k. Summary of my Activities and Future Plans

My current areas of research and professional activities focus on the fields of intellectual property policy, management and exploitation of knowledge assets, technology transfer, innovation entrepreneurship, health systems reform and health technology assessment (HTA).

My contribution to academic research and related policy activities focuses on five central areas.

The first area deals with the political economy of intellectual property rights (IPRs) in general and the interaction between intellectual property (IP) performance and the activities of interested groups (e.g. pharmaceutical companies) in particular. My first book, *The International Political Economy of Intellectual Property Rights*, which was published by academic publishers Edward Elgar in 2004, significantly contributed to the understanding of the dynamic dimension of the IP environment in the pharmaceutical field. In the following years, I widened my research drawing special attention to the manner in which interested groups attempt to influence the IP environment at different strata. I also published several important articles and chapters that compared the behaviour of interested groups in the pharmaceutical and software fields (for example *Political Economy of Intellectual Property Policy-Making: Theory and Practice*", *Journal of World Investment and Trade*, vol. 7:2, April 2006).

The second area deals with the creation and enforcement of international agreements in the IP arena on a multilateral, regional and bilateral level. My research emphasizes the different approaches towards IP-related trade policies in international agreements, adopted

by leading nations, such as the U.S.A and Europe. For example my article - *The International Regulation of IPRs in a TRIPS and TRIPS plus World*, *Journal of World Investment and Trade* vol. 6:3, July 2005 has received much attention and is used as a data source by different organisations (such as the international center for trade and sustainable development, ICTSD) and cited by different scholars. At the request of various organisations (such as the European Center of International Political Economy (ECIPE), International Trade Policy Unit of the London School of Economics, etc), this study was subsequently adapted, updated and expanded and presented in reports. Some of my studies were published by the European Parliament, for example: **Pugatch, M.P.**, Torstensson, D. *The impact of the Anti-Counterfeiting Trade Agreement (ACTA) on Access to Medicines in Developing Countries*, Report Submitted to Enterprise LSE as part of a workshop of the European Parliament, Directorate General for External Policies on The Anti-Counterfeiting Trade Agreement (ACTA) (June 2012), 19 p.

The third area deals with the various components of IP rights in the biotechnological and pharmaceutical sectors. My work on these issues has contributed to the understanding of the theoretical and practical significance of the protection of medical files in the process of registration (data exclusivity). It has also contributed towards the manner in which it is possible to use compulsory licensing within the framework of international agreements (TRIPS) for the purpose of making medicines accessible in underdeveloped countries. Two particularly known publications of mine on this subject are: "*Intellectual Property and Pharmaceutical Data Exclusivity in the Context of Innovation and Market Access*", in: Vivas-Eugui, D. Tansey, G. and Roffe, P. (eds.) *Negotiating Health* (Earthscan & International Centre for Trade and Sustainable Development: Geneva, February 2006) and "*Much Ado About Nothing - the WTO TRIPS Deal on Drugs' Patents*", in: Debroy, B., Saqib, M. and Mitra, M. ed. *WTO at Ten: Looking Back to Look Beyond* (Konark Publishers: New Delhi, February 2005), vol.2, Chapter 11.; *Building the Bio-Economy Examining National Biotechnology Industry Development Strategies* (May 2014, Pugatch Consilium report, commissioned by BIO)

The fourth area in which I believe I have made an important contribution deals with the quantitative measurement of the IP environment. I was fortunate to develop the first index of its kind that measures the strength of the IP regime relating to the pharmaceutical industry and, recently, the software industry, in a quantitative manner in various countries. The importance of this index manifests itself in that it enables accurate measuring of the strength of the pharmaceutical IP regime in various countries. My research was first featured in *Journal of World Intellectual Property* - "*Measuring the Strength of National Pharmaceutical Intellectual Property Regimes: Creating a New Pharmaceutical IP Index*", vol. 9: 4 (July 2006). Since then the index has been expanded and published in numerous academic and professional journals, such as *Measuring the Strength of National Pharmaceutical Intellectual Property Regimes in Eight Countries: Using a Pharmaceutical IP Index to Benchmark India*", *Journal of World Investment and Trade*, vol.8:4 (August 2007)

The index is regularly cited in numerous professional journals and presentations. Indeed, in 2009 I was asked to revise and update my IP index and publish its results in *Managing Intellectual Property Magazine* (July 2009).

It is worth citing a review of this work by Prof Ian Cockborn of Boston University:

"To my knowledge, only Pugatch (2006) has worked on an index based on such a comprehensive set of indicators for assessing the strength of IPRs in this sector. Since the passage of the TRIPS Agreement, many countries have made significant changes to their patent laws in various of the dimensions listed above, and the diversity of these changes across countries presents interesting potential opportunities to identify their effects. Obviously, though, the effort required to collect data on all of these items is high: Pugatch has computed his index only for eight countries..... It should, therefore, be a priority to construct (and publish) this type of index for a wide range of countries; to do this both on a "look back" and continuing basis, e.g. 1990, 1995, 2000, 2005, 2010, and to use a similar methodology to construct indexes relevant to other sectors, e.g. the complex/cumulative technologies such as software, telecommunications, semiconductors." (Cockborn, I. M. 'Intellectual Property Rights and Pharmaceuticals: Challenges and Opportunities for Economic Research', *The Economics of Intellectual Property. Suggestions for Further Research in Developing Countries and Countries with Economies in Transition* (WIPO, 2009))

In 2012 I was asked by the US Chambers of Commerce to create a global cross sectorial index (the GIPC Index). The index is based on 30 indicators and covers 35 countries. The index is widely cited and used as a benchmark by different countries and industries.

Finally, over the last years I have diversified my research into additional areas such as health technology assessment (HTA), pricing and reimbursement and healthcare system reforms. Some of my publications, particularly in the area of political economy of HTA, have gained popularity and a reputation in the international arena (for example my recent co-authored paper - *Theory versus Practice: Discussing the Governance of Health Technology Assessment Systems* (Stockholm-Network: London, 2009) – has been published in German and also in Slovak (at the request of Dr. Darina Sedláková, MPH Head, WHO Country Office in Slovakia). Additionally, in 2010, I was interviewed by Nature Medicine (April 2010) with regard to my publication (co-authored): Torstensson D., Pugatch, M.P. *Keeping Medicines Safe - A Study of the Regulations Guiding the Approval of Medicines in Emerging Markets* (Stockholm-Network: London, 2010);

My current and future areas of interests would include the following:

- The political economy of intellectual property rights: I intend to continue to explore the interaction between intellectual property (IP) performance and the activities of interested groups (e.g. pharmaceutical companies), as well as further research the process of intellectual property policy making.
- The global intellectual property architecture: I intend to specifically focus on the creation and enforcement of international agreements in the IP arena on a multilateral, regional and bilateral level.
- Pharmaceutical intellectual property rights: I will be focusing on the various components of intellectual property rights in the biotechnological and pharmaceutical branches (i.e. patents, trademarks and data exclusivity).

- Indices of IPRs: I am interested in researching the quantitative measurements of intellectual property environments, especially in the pharmaceutical, content industries and IT sectors. In this context I intend to continue to update the Global Intellectual Property Index which was commissioned by the US Chambers of Commerce

- Innovation and technology transfer: I intend to focus on national innovation strategies in the biomedical fields and the energy sector, and on the utilization and transfer of knowledge by public bodies and academic institutions (Bayh-Dole, tech-transfer offices, among others).

- Health technology assessment (HTA): I will be researching HTAs with a particular focus on the political economy of HTA systems in different countries.

Work in preparation - specific projects, planned publications and contributions to science:

In the near future I intend to focus on the following aspects:

1. Finalize my research into the systemic, macroeconomic and legal factors that contribute to the development of biotechnological capabilities, a research project by BIO
2. Carry out the 6th edition of the Biopharmaceutical Competitiveness Index (BCI) Survey, the purpose of which is to provide a comprehensive snapshot of different countries' attractiveness for biopharmaceutical investment, derived from the firsthand knowledge of experts and investors operating in each country.
3. Update the 10th Edition of the GIPC global intellectual property Index, expanding it to 50 countries
4. Update the 4th edition of the Global Rule of Law Business Dashboard (Commissioned by the US Chambers of Commerce)
5. Participate in the launch of the 6th Edition of the GIPC Index in Washington DC in February 2021
6. Co-organize and chair a forthcoming EIPIN Conference in Feb 2021 in Maastricht